Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07064395 · ClinicalTrials.gov registry record · NA
Bright Light Therapy on Sleep Health in Lung Cancer Patients
A NA study of Lung Cancers, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07064395: Recruiting NA study of Lung Cancers, sponsored by Henry Ford Health System.
NCT07064395 is a NA study of Lung Cancers that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 20 participants, below the 178-participant average among 5 other Lung Cancers trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07064395, a NA study of Lung Cancers, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are: * Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients? * Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging. Participants will: * Receive bright light exposure or usual light exposure every day for 4 weeks * Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests * Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks * Keep a daily sleep log
Primary Outcome
Changes in sleep patterns will be assessed by sleep efficiency (e.g., duration of sleep in hours), sleep quality (e.g., number of sleep disturbance), and sleep onset latency (e.g., minutes of falling asleep).
Conditions Studied
Interventions
- OTHER bright light
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
What NCT07064395 shows while recruiting
NCT07064395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 178-participant average among 5 other Lung Cancers trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Lung Cancers appearing as the primary indexed condition, and to 1 intervention - of which bright light is the first listed.
NCT07064395 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07064395 about?
NCT07064395 is a clinical study titled "Bright Light Therapy on Sleep Health in Lung Cancer Patients". The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are: * Does bright light ther...
What is the current status of trial NCT07064395?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-06-09. Estimated completion is 2026-02-28.
What conditions does trial NCT07064395 study?
This clinical trial studies the following conditions: Lung Cancers.
What interventions are being tested in trial NCT07064395?
The interventions under investigation include: bright light (OTHER).
Who is sponsoring clinical trial NCT07064395?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07064395 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
COMPLETED · NA
-
Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
RECRUITING · Phase 3
-
Rapid Autopsy and Procurement of Cancer Tissue
RECRUITING
-
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RECRUITING · Phase 1
-
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI